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Objective: We tested whether ischemic postconditioning (IPostC) is protective in remodeled myocardium.
Methods: Post-myocardial infarct (MI)-remodeled hearts after permanent coronary artery ligation and one kidney one clip (1K1C)
hypertensive hearts of male Wistar rats were exposed to 40 min of ischemia followed by 90 min of reperfusion. IPostC was induced by six
cycles of 10 s reperfusion interspersed by 10 s of no-flow ischemia. Activation of reperfusion injury salvage kinases was measured using
Western blotting and in vitro kinase activity assays.
Results: IPostC prevented myocardial damage in both MI-remodeled and 1K1C hearts, as measured by decreased infarct size and lactate
dehydrogenase release, and improved function. The reduction in infarct size and the recovery of left ventricular contractility achieved by
IPostC was less in 1K1C hearts, but was unchanged in MI-remodeled hearts when compared to healthy hearts. In contrast, the recovery of
inotropy was unaffected in 1K1C hearts, but was less in MI-remodeled hearts. Inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway
with LY294002 abolished the protective effects of IPostC on both disease models and healthy hearts. Western blot analysis in conjunction
with in vitro kinase activity assays identified protein kinase B (PKB)/Akt but not p42/p44 extracellular-signal regulated kinase 1/2 (ERK1/2)
as the predominant kinase in IPostC-mediated cardioprotection in remodeled hearts. IPostC increased phosphorylation of the PKB/Akt
downstream targets eNOS, GSK3β, and p70S6K in remodeled hearts.
Conclusion: Our results offer evidence that IPostC mediates cardioprotection in the remodeled rat myocardium primarily via activation of the
PI3K–PKB/Akt reperfusion injury salvage kinase pathway.
© 2006 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.Keywords: Cardiac remodeling; Ischemia–reperfusion injury; Postconditioning; Reperfusion injury salvage kinase; Cellular signaling⁎ Corresponding author. Cardiovascular Anesthesia Research Laboratory,
Center of Clinical Research, Institute of Anesthesiology, University Hospital
Zurich, Rämistrasse 100, CH-8091 Zurich, Switzerland. Tel.: +41 44 255 46 00;
fax: +41 44 255 44 09.
E-mail address: michael.zaugg@usz.ch (M. Zaugg).
1 Both authors equally contributed to this work.
0008-6363/$ - see front matter © 2006 European Society of Cardiology. Publish
doi:10.1016/j.cardiores.2006.06.0271. Introduction
Despite the powerful protective effects of precondition-
ing, the clinical application of this phenomenon has been
rather disappointing, mainly because preconditioning must
be instituted before the ischemic event [1]. In contrast, a
more promising approach to cardioprotection termed
“ischemic postconditioning” (IPostC) has been described
by Vinten–Johansen's group [2]. It consists of several cycles
of coronary occlusion/reperfusion started immediately at theed by Elsevier B.V. All rights reserved.
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ischemia. Unlike preconditioning, postconditioning theoret-
ically allows unrestricted application in the clinical settings,
and thus has attracted much attention over the past years.
Importantly, some pharmacological agents can afford
comparable protection when applied during early reperfu-
sion (“pharmacological postconditioning”) [3–5].
Recent studies revealed that IPostC exerts its protective
effects through the recruitment of prosurvival kinases such as
phosphatidylinositol 3-kinase (PI3K)–protein kinase B
(PKB)/Akt and the p42/p44 extracellular signal-regulated
kinase 1/2 (ERK1/2) pathways (also termed reperfusion
injury salvage kinase or RISK pathway) at the time of
reperfusion [6]. So far, nearly all experimental studies have
evaluated IPostC in healthy juvenile hearts. However, this is
far from clinical reality, where a high number of elderly
patients with cardiovascular disease would benefit most from
protection by IPostC. Hypertensive left ventricular hyper-
trophy and post-myocardial infarct (MI)-remodeled hyper-
trophy account for most of the clinically relevant cases of
cardiac hypertrophy and remodeling. These hypertrophied
and remodeled hearts, even during the compensated state, are
at greater risk to suffer severe ischemic damage and may be
less amenable to protection by postconditioning [7]. We
therefore tested whether protection by IPostC would be
diminished or lost in two highly controlled experimental
models of markedly remodeled hypertrophic hearts.
The data provided in this study show for the first time that
cardioprotection by IPostC is preserved in the remodeled
myocardium after permanent coronary artery ligation and in
one kidney one clip (1K1C) hypertensive rat hearts. Using in
vitro kinase assays to directly measure PKB/Akt and ERK1/
2 activities, we further identified PI3K–PKB/Akt as the
predominant RISK pathway for IPostC-induced protection in
both disease models.
2. Methods
This study was conducted in accordance with the
guidelines of the Animal Care and Use Committee of the
University of Zurich, Zurich, Switzerland. All experimental
procedures conformed to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes
of Health (NIH publication 85-23, revised 1996).
2.1. Cardiac hypertrophy models
Myocardial infarction (∼35% of left ventricular mass)
and subsequent hypertrophic remodeling was induced in
male adult (180–200 g, 8–9 weeks old) Wistar rats by
permanent ligation of the left anterior descending coronary
artery (LAD) under anesthesia, as previously described in
detail [8,9]. Sham-operated animals underwent the same
procedure except that the suture was passed under the
coronary artery without ligation. To induce hypertensive
cardiac hypertrophy, rats were subjected to right nephrecto-my and a silver clip (0.2 mm passage) was placed around the
left renal artery under anesthesia (1K1C) [10]. Control sham
rats (1K) had right nephrectomy without application of a
clip. Rats of both disease models were sacrificed 6 weeks
after surgery, and the body weight and heart weight were
measured. Systolic blood pressure was measured in awake
rats by means of the tail-cuff method.
2.2. Histology
Left ventricular tissue samples were fixed with 3.6%
formaldehyde and embedded in paraffin. 3-μm sections at
mid-ventricular level were subjected to Gomori's silver
staining and nuclear fast red for visualization of individual
myocytes in the viable left ventricular wall. The stained
sections were analyzed by microscopy using image analysis
(Zeiss KS 400, Germany).
2.3. Experimental protocol of isolated perfused rat hearts in
the Langendorff apparatus
Six weeks after surgery, rats were heparinized (500 units
i.p.) and 15 min later decapitated. Hearts were removed and
perfused in a non-circulating Langendorff apparatus with
Krebs–Henseleit buffer gassed with 95% O2 and 5% CO2 at
pH 7.4 and 37 °C [4]. Experimental conditions including
coronary flow and temperature were carefully monitored
throughout the protocols. After equilibration, perfusion
pressure was set at 80 mm Hg and left ventricular end-
diastolic pressure (LVEDP) at 10 mm Hg. Spontaneously
beating hearts were exposed to 40 min of global no-flow
ischemia (test ischemia) followed by 90 min of reperfusion
(Fig. 1). IPostC was induced by six cycles of 10 s reperfusion
interspersed by 10 s no-flow ischemia immediately after test
ischemia. Five hearts were assigned to each of the following
six groups: (1) CTL, time-matched perfusion without
ischemia; (2) ISCH, test ischemia followed by 90 min
reperfusion; (3) ISCH/LY, application of the PI3K inhibitor
LY294002 (15 μmol/l) during the first 15 min of reperfusion;
(4) IPostC, immediately applied after prolonged test
ischemia; (5) IPostC/LY, application of LY for 15 min
starting immediately at reperfusion in postconditioned
hearts; and (6) vehicle, application of 0.02% dimethyl
sulfoxide (DMSO) vehicle without LY294002 during 15 min
of reperfusion. The following parameters were recorded: left
ventricular developed pressure (LVDP) and derivatives
(±dp/dt), left ventricular end-diastolic pressure (LVEDP),
epicardial ECG, coronary flow (CF), and perfusion pressure.
Infarct size was determined by 1% 2,3,5-triphenyltetrazo-
lium chloride staining after 90 min of reperfusion [4]. In
addition, myocardial damage was estimated by measuring
the release of lactate dehydrogenase (LDH) from necrotic
tissue, as previously described [8]. Briefly, the perfusate was
collected and LDH activity was determined by the Roche/
Hitachi 917 kit (sensitivity 6 U/l, intra- and interassay
coefficients of variance b1%). For Western blot analysis and
Fig. 1. Treatment protocols. ISCH: hearts exposed to 40 min of test ischemia
followed by 90 min reperfusion. IPostC: ischemic postconditioning was
induced by 6 cycles of 10 s reperfusion followed by 10 s no-flow ischemia
right at the onset of reperfusion after 40 min of test ischemia. IPostC/LY:
postconditioned hearts exposed to the PI3K inhibitor LY294002 (15 μmol/l)
dissolved in vehicle (0.02% dimethyl sulfoxide (DMSO)) during the first
15 min of reperfusion. CTL: time-matched perfusion. Infarct size was
determined by 1% triphenyltetrazolium staining at the end of experiments
(n=5 hearts per experimental group). In separate experiments (n=4 hearts
per experimental group), phosphorylation (by Western blotting) and activity
of PKB/Akt and extracellular-signal regulated kinase 1/2 (ERK1/2) were
assayed after 15 min of reperfusion.
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group) were carried out and terminated after 15 min of
reperfusion.
2.4. mRNA extraction and real-time quantitative polymerase
chain reaction
Total RNAwas prepared using RNeasy Mini Kit (Qiagen).
First strand cDNAwas synthesized from 1.0 μg of total RNA
using SuperScript II reverse transcriptase (Invitrogen) andTable 1
Heart weight, body weight, and baseline cardiac function in the hypertrophic rat m
Rat model Healthy 1K1C model
Sham (1K)
HW (g) 1.203±0.089 1.204±0.070
BW (kg) 0.309±0.018 0.291±0.022
HW/BW (g/kg) 3.900±0.280 4.172±0.442
LVDP (mm Hg) 93.9±6.3 91.8±5.3
CF (ml/min) 13.1±1.2 12.9±1.1
HR (beats/min) 290±22 294±17
HW: heart weight; BW: body weight; LVDP: left ventricular developed pressure; CF
healthy controls. 1K1C: one kidney one clip rat model; sham (1K), nephrectomy
hearts (permanent coronary artery ligation); sham: sham-operated rats (a suture was
model groups were used 6 weeks after surgery. Data are mean±S.D. (n=20 for sh
* pb0.001 vs. sham and healthy groups.oligo-dT as primer. Real-time quantitative PCR was per-
formed as previously described [8] using the following
primers: atrial natriuretic peptide (ANP), 5′–ATCAC
CAAGGGCTTCTTCCT–3′ (sense) and 5′–TGTTGGA
CACCGCACTGTAT–3′ (antisense); and α-skeletal actin
(α-skl-actin), 5′–CACGGCATTATCACCAACTG–3′
(sense) and 5′–CCGGAGGCATAGAGAGACAG–3′ (anti-
sense). α-Tubulin was used for normalization with the sense
and antisense primers 5′–CCATGCGTGAGTGTATCTCC–
3′ and 5′–GTGCCAGTGCGAACTTCATC–3′, respectively.
2.5. Western blot analysis
Western blot analysis was carried out as previously
described [8]. The antibodies used were from the following
sources: glycogen synthase kinase 3β (GSK3β), p70S6K,
endothelial nitric oxide synthase (eNOS), ERK1/2, phospho-
PKB/Akt (Ser473), phospho-GSK3β (Ser9), phospho-
p70S6K (Thr389), phospho-eNOS (Ser1177), phospho-
ERK1/2 (Thr202/Tyr204) (Cell Signaling Technology);
monoclonal antibodies against pan-actin (Chemicon) and
α-tubulin (Sigma); polyclonal antibody against ANP (Santa
Cruz); polyclonal antibody against α-skl-actin was a gift
from Dr. Christine Chaponnier (Department of Pathology,
University of Geneva, Geneva, Switzerland); polyclonal anti-
PKB/Akt antibody (Ab10) was a gift from Dr. Brian A.
Hemmings (Friedrich Miescher Institute, Basel, Switzerland).
2.6. Immunoprecipitation and in vitro kinase assay
Left ventricular non-infarcted tissue (transmural) was
extracted in ice-cold lysis buffer (25 mmol/l Tris–HCl, pH
7.4, 120 mmol/l NaCl, 2 mmol/l ethylenediamine tetraacetic
acid, 1% Triton X-100, 0.5% Nonidet P-40, 1 mmol/
l phenylmethylsulfonyl fluoride, 1 mmol/l benzamidine,
0.1 mmol/l sodium orthovanadate, 10 mmol/l sodium
fluoride, and 1 μmol/l microcystin-LR). Extracts were
centrifuged (16000×g, 30 min, 4 °C), and protein concen-
trations determined using the Bradford assay. Tissue extracts
(1 mg protein) were incubated at 4 °C for 2 h on a shakingodels
Infarct model
1K1C Sham MI-remod
1.927±0.191⁎ 1.150±0.104 1.598±0.083⁎
0.289±0.017 0.302±0.020 0.296±0.020
6.684±0.695⁎ 3.817±0.401 5.428±0.413⁎
112.5±10.4⁎ 91±4.0 67.7±5.6⁎
13.4±1.3 13.1±3.2 13.4±1.3
293±17 293±14 295±17
: coronary flow; HR: heart rate; healthy: age-matched rats (300 g) serving as
without applying a clip (one kidney); MI-remod: postinfarct-remodeled rat
passed under the coronary artery without ligation). Rats in the hypertrophic
am (1K) and sham, n=30 for healthy, 1K1C, and MI-remod).
Fig. 2. Infarct size (panel A), lactate dehydrogenase release (panel B) and contractility parameters (panels C–F) of healthy, 1K1C, and MI-remodeled hearts. Left
ventricular developed pressure (LVDP) (panel C), +dp/dt (panel D), left ventricular end-diastolic pressure (LVEDP) (panel E), and −dp/dt (panel F) were
determined at 90 min of reperfusion and are indicated as percentage of baseline or mmHg (LVEDP). ISCH: hearts exposed to 40 min of test ischemia followed by
90 min reperfusion. IPostC: ischemic postconditioning. IPostC/LY: postconditioned hearts exposed to the PI3K inhibitor LY294002 (15 μmol/l) during first
15 min of reperfusion. CTL: time-matched perfusion. Data are mean±S.D. (n=5 per group). *pb0.05 vs. ISCH and †pb0.05 vs. same treatment in healthy
hearts.
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antibody coupled to 10 μl protein A-sepharose (Amersham
Biosciences) or monoclonal anti-ERK1/2 (Zymed, clone
ERK-7D8) coupled to 10 μl protein G-sepharose (Amersham
Biosciences). The immune-complexes were then washed 4
times with lysis buffer, once with kinase buffer (25 mmol/
l Tris–HCl, pH 7.4, 10 mmol/l MgCl2, 1 mmol/l dithiothrei-
tol, 1 μmol/l PKI, and 1 μmol/l microcystin-LR), and finally
resuspended in 20 μl of kinase buffer. For PKB kinase assay,
the reaction was started with 60 μmol/l of Crosstide
(GRPRTSSFAEG) and 20 μmol/l of [γ-32P] ATP (Amer-
sham Biosciences) in a final volume of 30 μl, incubated atFig. 3. Phosphorylation status (panel A) and kinase activity (panel B) of protein kina
PKBS473/total-PKB for each group. Data are mean±S.D. (n=4 per group). *pb0.30 °C for 60 min, and stopped by addition of trichloroacetic
acid (TCA) to a final concentration of 10%. After brief
centrifugation, 20 μl aliquots were removed and spotted onto
P81 phosphocellulose paper. The paper was washed
immediately for 10 min with 75 mmol/l phosphoric acid
(4 times), dried, and 32P incorporation determined by
Cerenkov counting. For ERK1/2 kinase assay, the reaction
was started with 4 μg of myelin basic protein and 20 μmol/
l of [γ-32P] ATP in a final volume of 30 μl and incubated at
30 °C for 30 min. The reaction was terminated by addition of
SDS-sample buffer and boiled at 95 °C for 5 min. Aliquots
were subjected to SDS–PAGE (15%) followed byse B/Akt (PKB). RepresentativeWestern blots and average density ratio of p-
05 vs. ISCH.
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One unit of activity was defined as the amount of enzyme
that transferred 1 pmol phosphate/min to the substrate at
30 °C.Fig. 4. Phosphorylation status of glycogen synthase kinase3β (GSK3β) (panel A).
total-GSK3β. Phosphorylation status of endothelial nitric oxide synthase (eNOS) (pan
total-eNOS. Data are mean±S.D. (n=4 per group). *pb0.05 vs. ISCH.2.7. Statistics
Data are presented as mean±S.D. For the cardiac
functional data, repeated-measures analysis of variance wasRepresentative Western blots and average density ratio of p-GSK3βS9/
el B). Representative Western blots and average density ratio of p-eNOSS1177/
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Unpaired t-test was used to compare groups at identical time
points, and paired t-test to compare within groups over time.
p values were multiplied by the number of comparisons
(Bonferroni correction). Tukey's post-hoc test was applied
for multiple comparisons of the one-way analysis of variance
for all other data. pb0.05 was considered as significant.
SigmaStat (version 2.0; SPSS Science, Chicago, IL) was
used for the analyses.
3. Results
3.1. Characterization of remodeling and hypertrophy in
diseased hearts
Heart- (HW) and body- (BW) weight as well as their ratio
(HW/BW) are summarized in Table 1 for the two disease
models. HW and HW/BW were significantly higher in the
1K1C and the MI-remodeled (permanent coronary artery
ligation) groups, as compared to the healthy and sham
groups indicating cardiac hypertrophy in both disease
models. Table 1 also shows LVDP, CF, and heart rate (HR)
ex vivo at equilibration on the Langendorff apparatus.
LVDP was significantly higher in the 1K1C and lower in
the MI-remodeled groups than in healthy or sham controls,
while CF and HR were unchanged. The higher LVDP
observed at the Langendorff apparatus corresponds to the
significantly (pb0.001) higher systolic blood pressure
measured in vivo in 1K1C (186±18 mm Hg, n=30)Fig. 5. Phosphorylation status of ribosomal S6 kinase (p70S6K). Representative We
mean±S.D. (n=4 per group). *pb0.05 vs. ISCH.compared to sham (1K) (123±10 mm Hg, n=20) and
healthy age-matched animals (120±9 mm Hg, n=10). The
post-infarct remodeling in MI-remodeled hearts has been
characterized in detail in our previous study [8]. The 1K1C
hearts displayed an increase in mRNA of about 10-fold for
ANP and 4-fold for α-skl-actin, which was accompanied by
an increase in protein levels as well (Supplementary Fig.
S1A and B). Micrographs of cross-sections of the left
ventricular free wall at the mid-ventricular level of 1K1C and
MI-remodeled hearts displayed enlarged myocytes in
comparison to sham controls (Supplementary Fig. S1C).
3.2. Cardioprotection by ischemic postconditioning is
preserved in remodeled myocardium
IPostC significantly improved functional recovery and
decreased infarct size in both the 1K1C as well as the MI-
remodeled hearts, when compared to unprotected remodeled
hearts (Fig. 2A–F and Supplementary Tables 1–3). IPostC
achieved over 80% reduction in infarct size and LDH release
in MI-remodeled and healthy hearts, while in 1K1C hearts the
reduction of both parameters was somewhat lower (69%)
(Fig. 2A and B). With regard to hemodynamics, the recovery
of LVDP was lower in 1K1C hearts as compared to MI-
remodeled and healthy controls after application of IPostC
(Fig. 2C). On the other hand, the rate of pressure rise (+dp/dt,
inotropy) was fully preserved in 1K1C, while it was lower by
38% inMI-remodeled hearts (Fig. 2D). The baseline values of
LVDP and inotropywere significantly lower inMI-remodeledstern blots and average density ratio of p-p70S6KT389/total-p70S6K. Data are
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mentary Table 3). During reperfusion, LVEDP was increased
and lusitropy was decreased in 1K1C hearts compared to
healthy hearts, indicating impaired postischemic diastolic
function in 1K1C hearts. The protection by IPostC was
completely abolished by co-administration of the PI3K
inhibitor LY294002 (Fig. 2A–F, and Supplementary Tables
1–3). LY294002 or the solvent dimethyl sulfoxide alone
administered during reperfusion did not affect functional
recovery or infarct size (data not shown). These results
provide strong evidence that PI3K-dependent protection by
IPostC is preserved and operative in both disease models.Fig. 6. Phosphorylation status (panel A) and kinase activity (panel B) of extracellu
averaged density ratio of p-ERK1/2T202/Y204/total-ERK1/2 for each group. Data ar3.3. Ischemic postconditioning in remodeled myocardium
activates PKB/Akt and its downstream targets GSK3β,
eNOS, and p70S6K in a PI3K-dependent manner
Activation of the pro-survival PI3K–PKB/Akt signaling
pathway has been shown to be important for cardioprotection
in several healthy animal models [4,5,11–14]. Here we show
that IPostC significantly increased phosphorylation of PKB/
Akt (Fig. 3A) and its downstream targets GSK3β, eNOS,
and p70S6K in remodeled hearts (Figs. 4 and 5). IPostC-
induced phosphorylation of PKB/Akt and its downstream
substrates GSK3β, eNOS, and p70S6K was suppressed bylar-signal regulated kinase 1/2 (ERK1/2). Representative Western blots and
e mean±S.D. (n=4 per group). *pb0.05 vs. ISCH.
160 M. Zhu et al. / Cardiovascular Research 72 (2006) 152–162LY294002. Dimethyl sulfoxide alone had no effect on the
phosphorylation of PKB/Akt when compared to the ischemia
group (data not shown). To further characterize the activation
status of PKB/Akt, an in vitro kinase assay was carried out.
Consistent with the results fromWestern blots, the activity of
PKB/Akt was significantly elevated by IPostC compared to
the ischemic control and completely abolished by LY294002
(Fig. 3B). Phosphorylation and enzyme activity of PKB/Akt
were partially increased by ischemia alone compared to the
time-matched controls in both healthy and MI-remodeled
hearts. However, this was not observed in the 1K1C hearts
(Fig. 3A and B). Taken together, the data underscore the
unique role of PKB/Akt signaling in the IPostC-mediated
protection of the remodeled myocardium.
3.4. Cardioprotection by ischemic postconditioning in the
remodeled myocardium does not primarily depend on
ERK1/2 signaling
Beside PI3K–PKB/Akt, ERK1/2 signaling presents
another component in the RISK pathways that has also
been suggested to contribute to the reduction of infarct size
with postconditioning [13]. We therefore examined whether
the protection by IPostC would be associated with activation
of the ERK1/2 pathway in the remodeled hearts. In healthy
hearts, phosphorylation of ERK1/2 was moderately increased
(p=0.033) by ischemia alone, and was further enhanced
by IPostC (Fig. 6A). In 1K1C hearts, phosphorylation of
ERK1/2 was not increased by ischemia alone but was
increased by IPostC (Fig. 6A). The elevated phosphorylation
of ERK1/2 by IPostC was reversed by LY294002 suggesting
a PI3K-dependent phosphorylation of ERK1/2. In contrast,
phosphorylation of ERK1/2 in the MI-remodeled hearts was
strongly increased by ischemia alone, but was resistant to
LY294002 and not further increased by IPostC, indicating
that a PI3K-independent mechanism was responsible for the
ischemia-induced ERK1/2 phosphorylation in the MI-
remodeled hearts. These results based on the phosphorylation
status of ERK1/2 suggest that the ERK1/2 pathway is
differentially regulated in the two types of remodeling. In
parallel, the activities of ERK1/2 were also determined by an
in vitro kinase assay. Surprisingly, there was no increase in
ERK1/2 activities by IPostC in both remodeling models as
well as in healthy hearts (Fig. 6B). Moreover, the activities of
ERK1/2 in the MI-remodeled hearts were 3-fold lower than
that in healthy and 1K1C hypertrophied hearts, suggesting
that subtle differences in the regulation of RISK pathways
may exist between the models. Collectively, our results based
on direct enzyme activity measurements indicate that the
ERK1/2 pathway is not primarily involved in IPostC-
mediated protection in both healthy and diseased hearts.
4. Discussion
Here we show for the first time that protection by IPostC
is preserved in two rat models of myocardial remodeling.IPostC was previously reported to be ineffective in limiting
infarct size in rabbits with hypercholesterolemia and
atherosclerosis [15]. However, our results are in accordance
with a most recent clinical trial by Staat and colleagues [16],
who postconditioned hearts of patients undergoing percuta-
neous coronary interventions with four episodes of 1-min
balloon inflations starting within 1 min of reflow. Using
creatine kinase release as a surrogate marker of infarct size,
these authors found that myocardial damage could be
reduced by 36%.
Myocardial remodeling is a short-term adaptive but long-
term maladaptive process to a variety of hemodynamic
conditions associated with increased cardiac work. Character-
istic structural changes [17], alterations in metabolism [18],
and cellular signaling [19–21] put the remodeled myocardium
at particular risk for further ischemic damage. Since most
individuals who experience acute ischemic heart disease have
underlying myocardial remodeling, we addressed the impor-
tant question whether the diseased remodeled myocardium is
still receptive to protection by IPostC using two experimental
models of remodeling. While 1K1C remodeled hearts develop
eccentric hypertrophy by volume overload [10], MI-remo-
deled hearts display a far more complex architectural re-
arrangement due to (i) loss of viable tissue and scar formation
(ii) volume overload by scar expansion (iii) pressure overload
induced by increasing volume overload [20]. Nonetheless,
hypertrophy is a hallmark of both types of remodeling. Since
these structural changes are associated with alterations in
neurohormonal activation and cellular signaling, we hypoth-
esized that remodeling may abolish innate protective mechan-
isms and render the heart more susceptible to ischemia.
Previous studies identified the survival kinases PI3K–
PKB/Akt and ERK1/2 as key players in the protection
afforded by IPostC in healthy myocardium [6]. However, the
relative importance of the two kinases in mediating the
protection remains controversial. A study investigating
pharmacological postconditioning by 5′-(N-ethylcarboxa-
mido) adenosine and bradykinin suggests that PKB/Akt is
upstream of ERK1/2 [5], while results from a more recent
study stress the pivotal role of ERK1/2 but not PI3K–PKB/
Akt in IPostC-mediated protection [13]. Moreover, Schwartz
et al. [14] reported that IPostC activates both PKB/Akt and
ERK1/2 but yet failed to protect against ischemic injury in
pigs. In the present study, we show that PKB/Akt is activated
and that its downstream targets GSK3β, eNOS, and p70S6K
are markedly phosphorylated by IPostC not only in the
healthy but also in the remodeled hearts. This phosphoryla-
tion is commensurate with functional and structural protec-
tion and is sensitive to inhibition by LY294002. Importantly,
our results on PKB/Akt activation are not solely based on
Western blot analysis using phosphor-specific antibodies, but
further rely on in vitro kinase assays, which directly measure
catalytic activity. Although we observed an increase in
ERK1/2 phosphorylation by IPostC in healthy and 1K1C
hearts, the directly measured catalytic activity of ERK1/2 was
not elevated by IPostC in healthy and diseased hearts.
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IPostC was not sufficient to protect. Hence our data suggest
that PI3K–PKB/Akt but not ERK1/2 is the predominant
mediator of IPostC-induced protection in both healthy and
diseased hearts. Of note, our study is the first to measure
ERK1/2 activation in IPostC by assessing the phosphoryla-
tion status in conjunction with in vitro activity measurements.
Earlier studies on ERK1/2 activity in pre- and postcondition-
ing exclusively relied onWestern blotting, whichmay, at least
in part, explain the controversial role of ERK1/2 in IPostC.
Nonetheless, our results cannot rule out the possibility of
some cross talk between ERK1/2 and PKB/Akt, and the two
pathways may also follow different spatio-temporal routes at
the onset of reperfusion in the heart. Therefore, additional
time-course and blocker experiments will be required to
ultimately delineate the role of PKB/Akt and ERK1/2 in
IPostC-mediated protection in remodeled myocardium.
We found noteworthy alterations in PKB and ERK1/2
signaling in the different disease models. First, although the
maximal activation of PKB/Akt can be achieved by IPostC
in all three models, partial activation of PKB/Akt by
ischemia alone was lost in 1K1C hearts. This observation
may explain the observed reduced protection by IPostC in
1K1C rats. Second, the profiles of ERK1/2 phosphorylation
in both types of remodeling and the basal kinase activity of
ERK1/2 in MI-remodeled hearts were different from those
observed in healthy hearts. These alterations suggest that key
players of the RISK pathway may be differentially regulated
by different types of cardiac remodeling. Finally, we found
that the recovery of inotropy achieved by IPostC was im-
paired in MI-remodeled hearts, while both recovery of LVDP
and infarct size reduction were unaffected. The reason for
these differences is unclear. A recent study using a transgenic
mouse model of hypertrophy with cardiac-specific expres-
sion of myristoylated PKB/Akt demonstrated that activation
of PKB/Akt alone is not sufficient for protection [22]. This
implies that additional PI3K-dependent but PKB/Akt-
independent signaling components may be required for full
cardioprotection. Thus, it is possible that such alternative
mechanisms are impaired in MI-remodeled hearts.
Ischemic preconditioning has been shown to be ineffec-
tive in MI-remodeled rabbit hearts [23], but proved its
efficacy in several hypertrophy models [24–27]. Despite
these partly promising results, the concept of precondition-
ing could not be successfully established in the clinical
setting. Therefore, recent interventions aimed at modifying
reperfusion, but IPostC may further jeopardize the diseased
heart. This could be avoided by utilizing pharmacological
agents mimicking the biological process of IPostC. Hence,
the understanding of the molecular mechanisms underlying
IPostC is of paramount importance and should be exploited
in additional studies. Importantly, future studies should
particularly investigate the effects of the disease-related
alterations in signaling on cardioprotection.
In summary, using a highly controlled experimental
setting, we show in our study that remodeled rat hearts withhypertrophy induced by infarction (permanent coronary
artery ligation) and 1K1C hypertension are still receptive to
protection by IPostC. Furthermore, we identified in these
models the PI3K–PKB/Akt signaling pathway as predom-
inant mediator of IPostC-induced cardioprotection.
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